Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Yumi Kambayashi; Kentaro Ohuchi; Hiromu Chiba; Erika Tamabuchi; Tasuku Nagasawa; Yoshihide Asano; Taku Fujimura

doi:10.1159/000524013

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Yumi Kambayashi, Kentaro Ohuchi, Hiromu Chiba, Erika Tamabuchi, Tasuku Nagasawa, Yoshihide Asano, Taku Fujimura

Research output: Contribution to journal › Article › peer-review

Abstract

Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.

Original language	English
Pages (from-to)	469-472
Number of pages	4
Journal	Case Reports in Oncology
Volume	15
Issue number	2
DOIs	https://doi.org/10.1159/000524013
Publication status	Published - 2022 May 2

Keywords

Adverse event
BRAF/MEK inhibitor
Melanoma
Rheumatoid arthritis
Tubulointerstitial nephritis

ASJC Scopus subject areas

Oncology

Access to Document

10.1159/000524013

Cite this

@article{2548b60ca52644da93ced593480a4ed2,

title = "Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy",

abstract = "Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.",

keywords = "Adverse event, BRAF/MEK inhibitor, Melanoma, Rheumatoid arthritis, Tubulointerstitial nephritis",

author = "Yumi Kambayashi and Kentaro Ohuchi and Hiromu Chiba and Erika Tamabuchi and Tasuku Nagasawa and Yoshihide Asano and Taku Fujimura",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s).",

year = "2022",

month = may,

day = "2",

doi = "10.1159/000524013",

language = "English",

volume = "15",

pages = "469--472",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "2",

}

TY - JOUR

T1 - Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

AU - Kambayashi, Yumi

AU - Ohuchi, Kentaro

AU - Chiba, Hiromu

AU - Tamabuchi, Erika

AU - Nagasawa, Tasuku

AU - Asano, Yoshihide

AU - Fujimura, Taku

PY - 2022/5/2

Y1 - 2022/5/2

N2 - Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.

AB - Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.

KW - Adverse event

KW - BRAF/MEK inhibitor

KW - Melanoma

KW - Rheumatoid arthritis

KW - Tubulointerstitial nephritis

UR - http://www.scopus.com/inward/record.url?scp=85130429710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130429710&partnerID=8YFLogxK

U2 - 10.1159/000524013

DO - 10.1159/000524013

M3 - Article

AN - SCOPUS:85130429710

SN - 1662-6575

VL - 15

SP - 469

EP - 472

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 2

ER -

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this